A phase II study of paclitaxel for the treatment of ovarian stromal tumors: An NRG Oncology/ Gynecologic Oncology Group Study
详细信息 查看全文
- 作者：Elizabeth R. Burtona ; eburton@abingtonhealth.org" class="auth_mail" title="E-mail the corresponding author ; Mark Bradyb ; mbrady@gogstats.org" class="auth_mail" title="E-mail the corresponding author ; Howard D. Homesleyc ; homesleyh@ecu.edu" class="auth_mail" title="E-mail the corresponding author ; Peter G. Rosed ; rosep@ccf.org" class="auth_mail" title="E-mail the corresponding author ; Toshiaki Nakamurae ; nakamura@ml.kch.kagoshima.kagoshima.jp" class="auth_mail" title="E-mail the corresponding author ; Joshua P. Kestersonf ; jkesterson@hmc.psu.edu" class="auth_mail" title="E-mail the corresponding author ; Jacob Rotmenschg ; Jacob_rotmensch@rush.edu" class="auth_mail" title="E-mail the corresponding author ; J. Tate Thigpenh ; jthigpen@umc.edu" class="auth_mail" title="E-mail the corresponding author ; Linda Van Lei ; lvl@med.unc.edu" class="auth_mail" title="E-mail the corresponding author
- 关键词：Stromal tumor of ovary ; Paclitaxel
- 刊名：Gynecologic Oncology
- 出版年：2016
- 出版时间：January 2016
- 年：2016
- 卷：140
- 期：1
- 页码：48-52
- 全文大小：290 K
文摘
- •
Paclitaxel has activity in recurrent, malignant stromal tumor of the ovary.
- •
There was a complete response in 3.2% and partial response in 25.8% of women.
- •
Inhibin is not a reliable tumor marker.